These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28114907)

  • 1. The temporal impact of aging on the burden of herpes zoster.
    Varghese L; Standaert B; Olivieri A; Curran D
    BMC Geriatr; 2017 Jan; 17(1):30. PubMed ID: 28114907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
    Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
    BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific.
    Chen J; Abrahamson PE; Ke Y; Ong CR; Parikh R; Shantakumar S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2344983. PubMed ID: 38767209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of herpes zoster complications in older adults: A cohort study of US claims database.
    Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
    Vaccine; 2019 Feb; 37(9):1235-1244. PubMed ID: 30685248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals.
    Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
    Vaccine; 2018 Oct; 36(45):6810-6818. PubMed ID: 30249425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
    Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
    Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing trends of herpes zoster in Australia.
    MacIntyre R; Stein A; Harrison C; Britt H; Mahimbo A; Cunningham A
    PLoS One; 2015; 10(4):e0125025. PubMed ID: 25928713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
    Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
    Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults.
    Karki S; Newall AT; MacIntyre CR; Heywood AE; McIntyre P; Banks E; Liu B
    PLoS One; 2016; 11(8):e0160446. PubMed ID: 27483007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual incidence rates of herpes zoster among an immunocompetent population in the United States.
    Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
    BMC Infect Dis; 2015 Nov; 15():502. PubMed ID: 26546419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology.
    Goldman GS
    Vaccine; 2005 May; 23(25):3349-55. PubMed ID: 15837242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.
    Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Muthukumar A; Devine F; Sundar M; Bogart M; Hagopian E; Poston S; Duh MS; Oppenheimer JJ
    BMJ Open Respir Res; 2024 Jun; 11(1):. PubMed ID: 38862238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease Burden Due to Herpes Zoster among Population Aged ≥50 Years Old in China: A Community Based Retrospective Survey.
    Li Y; An Z; Yin D; Liu Y; Huang Z; Xu J; Ma Y; Tu Q; Li Q; Wang H
    PLoS One; 2016; 11(4):e0152660. PubMed ID: 27055179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes zoster in older adults: Impact on carbon footprint in the United States.
    Curran D; Bitetti J; Catterall I; Wincott S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2335722. PubMed ID: 38698759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization and costs associated with herpes zoster in the US.
    Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
    J Med Econ; 2016 Oct; 19(10):928-35. PubMed ID: 27149530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projections of zoster incidence in Australia based on demographic and transmission models of varicella-zoster virus infection.
    Costantino V; Gidding HF; Wood JG
    Vaccine; 2017 Dec; 35(48 Pt B):6737-6742. PubMed ID: 29050801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.
    Insinga RP; Itzler RF; Pellissier JM
    Pharmacoeconomics; 2007; 25(2):155-69. PubMed ID: 17249857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
    Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
    Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of herpes zoster in a United States administrative database.
    Insinga RP; Itzler RF; Pellissier JM; Saddier P; Nikas AA
    J Gen Intern Med; 2005 Aug; 20(8):748-53. PubMed ID: 16050886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.